Discovered in 1973 by Loren Pickart and shown in Nature to prolong liver cell survival 17 , it has since accumulated more than 50 years of peer-reviewed research on collagen and elastin synthesis, fibroblast activation, gene-expression modulation, and wound healing
Potential side effects include: Because its still being studied, its not FDA-approved for weight lossbut its being widely used in clinical peptide therapy protocols under supervised care
It is the active ingredient in the Health Canada-approved drug Egrifta, originally developed by Theratechnologies of Montral, Qubec
Richie JP Jr, et al
Examples include intractable vomiting causing dehydration, severe abdominal pain, or persistent symptoms that do not respond to conservative management
Peptyd BPC-157 jest oglnie bardzo dobrze tolerowany przez wikszo ludzi, gdy stosowany jest w zalecanych dawkach do 500 mcg, Zalecane dawkowanie BPC-157 to 200 mcg raz dziennie w celach leczniczych